New Treatment Guidelines for Sjögren's Disease.

[1]  H. Scofield,et al.  Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain , 2017, Arthritis care & research.

[2]  Theresa L. Ford,et al.  Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention. , 2016, Journal of the American Dental Association.

[3]  P. Asbell,et al.  Clinical guidelines for management of dry eye associated with Sjögren disease. , 2015, The ocular surface.

[4]  P. Ravaud,et al.  Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. , 2014, JAMA.

[5]  Gerd Geerling,et al.  Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications , 2014, Acta ophthalmologica.

[6]  A. Manzo,et al.  Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study , 2013, Arthritis Research & Therapy.

[7]  S. Carsons,et al.  Occurrence of Rheumatoid Arthritis Requiring Oral and/or Biological Disease-Modifying Antirheumatic Drug Therapy Following a Diagnosis of Primary Sjögren Syndrome , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[8]  E. Hachulla,et al.  Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients. , 2010, Rheumatology.

[9]  D. Isenberg,et al.  Estimating Indirect Costs in Primary Sjögren’s Syndrome , 2010, The Journal of Rheumatology.

[10]  A. Vissink,et al.  Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. , 2010, Arthritis and rheumatism.

[11]  Y. Konttinen,et al.  Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA‐deficient patients with primary Sjögren's Syndrome , 2010, Arthritis care & research.

[12]  A. Vissink,et al.  Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment , 2009, Annals of the rheumatic diseases.

[13]  B. Segal,et al.  Oral involvement in primary Sjögren syndrome. , 2008, Journal of the American Dental Association.

[14]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[15]  J. Cerhan,et al.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. , 2008, Blood.

[16]  R. Geenen,et al.  Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial , 2007, Annals of the rheumatic diseases.

[17]  L. Jacobsson,et al.  Effects of exercise on aerobic capacity and fatigue in women with primary Sjogren's syndrome. , 2007, Rheumatology.

[18]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[19]  R. Geenen,et al.  Safety and efficacy of leflunomide in primary Sjögren’s syndrome: a phase II pilot study , 2007, Annals of the rheumatic diseases.

[20]  R. Weinstein,et al.  Rituximab treatment in patients with IVIg‐dependent immune polyneuropathy: A prospective pilot trial , 2007, Muscle & nerve.

[21]  X. Mariette,et al.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.

[22]  A. Vissink,et al.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. , 2005, Arthritis and rheumatism.

[23]  M. Dougados,et al.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases , 2004, Annals of the rheumatic diseases.

[24]  S. Pillemer,et al.  Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. , 2004, Arthritis and rheumatism.

[25]  G. Baron,et al.  Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). , 2004, Arthritis and rheumatism.

[26]  J. Doyle,et al.  Utility assessment among patients with dry eye disease. , 2003, Ophthalmology.

[27]  G. Feder,et al.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project , 2003, Quality & safety in health care.

[28]  O. Honda,et al.  Pulmonary Involvement in Primary Sjögren's Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings in 60 Patients , 2001, Journal of thoracic imaging.

[29]  P. Petersen,et al.  Dental caries and dental health behavior of patients with primary Sjo¨gren syndrome , 2001 .

[30]  C. Ekdahl,et al.  Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36 , 2000, Scandinavian Journal of Rheumatology.

[31]  M. Yaron,et al.  Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers , 1999, Annals of the rheumatic diseases.

[32]  H. Moutsopoulos,et al.  Methotrexate in primary Sjögren's syndrome. , 1996, Clinical and experimental rheumatology.

[33]  C. Bucca,et al.  Respiratory function in systemic lupus erythematosus: relation with activity and severity , 1996, Lupus.

[34]  W. Richardson,et al.  The well-built clinical question: a key to evidence-based decisions. , 1995, ACP journal club.

[35]  F. Howell,et al.  Treatment of primary Sjögren's syndrome with hydroxychloroquine. , 1988, The American journal of medicine.

[36]  B. Segal.  Fatigue in Primary Sjögren’s Syndrome , 2011 .

[37]  C. Gordon,et al.  Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. , 2007, Rheumatology.

[38]  Christopher Snyder,et al.  The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. , 2005, Investigative ophthalmology & visual science.

[39]  J. Hetta,et al.  Anxiety and depression in patients with primary Sjögren's syndrome. , 2000, The Journal of rheumatology.

[40]  D. Isenberg,et al.  Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS), and primary SS. , 1998, The Journal of rheumatology.

[41]  G. Pasero,et al.  Fibromyalgia features in patients with primary Sjögren's syndrome. Evidence of a relationship with psychological depression. , 1989, Scandinavian journal of rheumatology.